Cipla’s arm inks distribution pact with Serum Institute of India

20 Nov 2014 Evaluate

Cipla’s wholly owned subsidiary, Cipla Europe NV has signed a distribution agreement with Serum Institute of India (SII), a global leader in the production of vaccines. Under the agreement, SII will develop and manufacture paediatric vaccines, while Cipla will seek European Medicines Agency approval and market the products in Europe.

This collaboration with SII enables Cipla to enter into the vaccines segment, continuing our commitment to inclusive healthcare for the world. The vaccines will be manufactured in Serum’s world class production facilities approved by World Health Organisation (WHO).

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Its portfolio includes 2000 products in 65 therapeutic categories with one quality standard globally.

Cipla Share Price

1520.55 -0.65 (-0.04%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×